Global Drug-Device Combination Market Set To Grow To $184bn By 2021

13 August 2018
Pharma

Visiongain has launched a new pharma report Global Drug-Device Combination Market 2017-2027: Drug Eluting Stents, Photosensitizers, Orthopaedic Products, Infusion Pumps, Wound Care Products, Transmucosal Products, Transdermal Patches, Hospital & Clinics, Ambulatory Surgical Centres, Emergency Service Centres, Home Care Settings

Combination products are being increasingly used in patients suffering from chronic disorders such as cardiac disease, cancer, diabetes, and multiple sclerosis among others. Owing to these products, a new dynamic has been initiated in the medical product development, regulatory approval as well as corporate interaction. Over the last decade, various regulatory agencies have developed numerous competences and regulations due to the rising integration of drugs and devices occurring in the latest generation of combination products.

The lead analyst of the report commented “the Drug-Device combination market is driven by initiatives from governments and NGOs in support of drug delivery implants, a rise in the usage of minimally invasive surgeries, technological innovations and advancements, and increasing prevalence of chronic disorders. However, regulatory challenges pertaining to recall of products due to adverse effects, technical challenges related to drug delivery and higher cost of the products are some of the factors hampering the growth of the Drug-Device combination market.”

Leading companies featured in the report include Medtronic, Boston Scientific Corporation, Stryker Corporation, Ethicon Inc, C.R. Bard Inc., Medline Industries Inc., Mylan Inc., Terumo Corporation, Pinnacle Biologics Inc., and W. L. Gore & Associates, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever